Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2024-520418-22-00
Authorised, recruiting Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.

2024-520418-22-00 · tracked via the Priya Life Science EU tracker
Sponsor
Glaxosmithkline Research & Development Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
24/11/2025
Enrollment target
453
Sites
Slovakia, Denmark, France, Sweden, Ireland, Belgium, Netherlands, Spain, Croatia, Germany, Poland, Hungary, Norway, Portugal

Condition studied

Chronic Obstructive Pulmonary Disease

Investigational medicinal product(s)

Novolizer Salbutamol 100 microgrammes/dosepoudre pour inhalationSterile 0.9% (w/v) sodium chloride solution in single-use PFS

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Annualized rate of moderate/severe exacerbations.

Endpoint detail

1. Time to first moderate/severe exacerbation., 2. Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score at Week 52., 3. Change from baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) total score at Week 52., 4. Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization, 5. Annualized Rate of Severe Exacerbations

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-520418-22-00 on CTIS ↗ ← All trials in the EU